Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sinkovits

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Thrombosis and Haemostasis|January 21, 2022
Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and MortalityGyörgy Sinkovits, Marienn Réti, Veronika Müller, et al.
Scientometrics|February 23, 2023
Use of accounting concepts to study research: return on investment in XSEDE, a US cyberinfrastructure serviceCraig A Stewart, Claudia M Costa, Julie A Wernert, et al.
International Journal of Molecular Sciences|September 28, 2024
Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19Flóra Demeter, György Bihari, Dorina Vadicsku, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Journal of Virology|June 14, 2013
Capsid antibodies to different adeno-associated virus serotypes bind common regionsBrittney L Gurda, Michael A DiMattia, Edward B Miller, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Frontiers in Immunology|April 13, 2023
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of <i>MBL2</i> genotype subgroupsLisa Hurler, Ágnes Szilágyi, Federica Mescia, et al.
Frontiers in Medicine|May 16, 2022
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort StudyBrandon M Henry, György Sinkovits, Ivan Szergyuk, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Nature|December 13, 2002
Overview of the Alliance for Cellular SignalingAlfred G Gilman, Melvin I Simon, Henry R Bourne, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Thrombosis and Haemostasis|January 21, 2022
Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and MortalityGyörgy Sinkovits, Marienn Réti, Veronika Müller, et al.
Scientometrics|February 23, 2023
Use of accounting concepts to study research: return on investment in XSEDE, a US cyberinfrastructure serviceCraig A Stewart, Claudia M Costa, Julie A Wernert, et al.
International Journal of Molecular Sciences|September 28, 2024
Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19Flóra Demeter, György Bihari, Dorina Vadicsku, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Journal of Virology|June 14, 2013
Capsid antibodies to different adeno-associated virus serotypes bind common regionsBrittney L Gurda, Michael A DiMattia, Edward B Miller, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Frontiers in Immunology|April 13, 2023
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of <i>MBL2</i> genotype subgroupsLisa Hurler, Ágnes Szilágyi, Federica Mescia, et al.
Frontiers in Medicine|May 16, 2022
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort StudyBrandon M Henry, György Sinkovits, Ivan Szergyuk, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Nature|December 13, 2002
Overview of the Alliance for Cellular SignalingAlfred G Gilman, Melvin I Simon, Henry R Bourne, et al.
Pageof 8